NO20073764L - Sammensetninger for behandling av HCV - Google Patents

Sammensetninger for behandling av HCV

Info

Publication number
NO20073764L
NO20073764L NO20073764A NO20073764A NO20073764L NO 20073764 L NO20073764 L NO 20073764L NO 20073764 A NO20073764 A NO 20073764A NO 20073764 A NO20073764 A NO 20073764A NO 20073764 L NO20073764 L NO 20073764L
Authority
NO
Norway
Prior art keywords
hcv
compositions
treatment
agent
compound
Prior art date
Application number
NO20073764A
Other languages
English (en)
Inventor
Kai Lin
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20073764L publication Critical patent/NO20073764L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelsen vedrører en farmasøytisk kombinasjon som omfatter a) et første middel som er et ikke-immunundertrykkende syklofilinbindende syklospsorin, f.eks. en forbindelse med formel I og b) et samtidigmiddel.
NO20073764A 2004-12-23 2007-07-19 Sammensetninger for behandling av HCV NO20073764L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867504P 2004-12-23 2004-12-23
PCT/US2005/046059 WO2006071619A1 (en) 2004-12-23 2005-12-20 Compositions for hcv treatment

Publications (1)

Publication Number Publication Date
NO20073764L true NO20073764L (no) 2007-09-18

Family

ID=36155247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073764A NO20073764L (no) 2004-12-23 2007-07-19 Sammensetninger for behandling av HCV

Country Status (16)

Country Link
US (1) US7897565B2 (no)
EP (1) EP1830871A1 (no)
JP (1) JP2008525459A (no)
KR (1) KR20070087624A (no)
CN (1) CN101076350A (no)
AU (1) AU2005322242B2 (no)
BR (1) BRPI0519345A2 (no)
CA (1) CA2587793A1 (no)
IL (1) IL183659A0 (no)
MA (1) MA29098B1 (no)
MX (1) MX2007007779A (no)
NO (1) NO20073764L (no)
NZ (1) NZ555143A (no)
RU (1) RU2007128099A (no)
WO (1) WO2006071619A1 (no)
ZA (1) ZA200703908B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
MX2007000503A (es) 2004-07-14 2007-03-08 Novartis Ag Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv).
EP1830871A1 (en) 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment
MX2007007721A (es) * 2004-12-23 2007-08-14 Novartis Ag Compuestos para el tratamiento de flaviviridae.
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
EP1909564A4 (en) * 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008043797A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Use of modified cyclosporins
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
WO2011053617A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
MX2012007076A (es) * 2009-12-18 2012-07-20 Boehringer Ingelheim Int Terapia combinada de hcv.
CN103179974A (zh) 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
US20130251678A1 (en) 2010-11-30 2013-09-26 Novartis Ag Bid dosage regimen for deb025
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN103476409A (zh) 2011-03-31 2013-12-25 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
KR20140010097A (ko) 2011-04-01 2014-01-23 노파르티스 아게 B형 간염 바이러스 단독 감염 또는 델타 간염 바이러스와의 조합 감염 및 연관된 간 질환의 치료
EP2696883A1 (en) 2011-04-13 2014-02-19 Novartis AG Treatment of hepatitis c virus infection with alisporivir
MX2014003753A (es) 2011-09-27 2014-05-01 Novartis Ag Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c.
CN104284671A (zh) 2012-05-07 2015-01-14 诺华股份有限公司 使用阿拉泊韦的药代动力学调节
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
TW201536789A (zh) 2013-07-29 2015-10-01 Enanta Pharm Inc Ｃ型肝炎病毒抑制劑
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AR031010A1 (es) * 2000-10-19 2003-09-03 Fujisawa Pharmaceutical Co Una composicion farmaceutica, util para inhibir el dano celular
AR036081A1 (es) * 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US7998492B2 (en) * 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
CN100335492C (zh) * 2002-12-23 2007-09-05 埃迪尼克斯(开曼)有限公司 生产3’－核苷前体药物的方法
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
AU2005290984B2 (en) * 2004-10-01 2010-09-09 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
EP1830871A1 (en) 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment

Also Published As

Publication number Publication date
EP1830871A1 (en) 2007-09-12
ZA200703908B (en) 2009-06-24
RU2007128099A (ru) 2009-01-27
NZ555143A (en) 2009-12-24
AU2005322242A1 (en) 2006-07-06
CA2587793A1 (en) 2006-07-06
AU2005322242B2 (en) 2010-02-11
BRPI0519345A2 (pt) 2009-01-20
WO2006071619A1 (en) 2006-07-06
MX2007007779A (es) 2007-08-14
US7897565B2 (en) 2011-03-01
US20090104149A1 (en) 2009-04-23
JP2008525459A (ja) 2008-07-17
CN101076350A (zh) 2007-11-21
KR20070087624A (ko) 2007-08-28
MA29098B1 (fr) 2007-12-03
IL183659A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20073764L (no) Sammensetninger for behandling av HCV
NO20092053L (no) HCV NS3-proteaseinhibitorer
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091707L (no) Inhibitorer av hepatitt C virus
NO20091704L (no) Inhibitorer av hepatitt C virus
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
ATE433447T1 (de) Pyrimiidinverbindungen
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20091706L (no) Inhibitorer av hepatitt C virus
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
GB0612423D0 (en) Therapeutic agents
NO20081844L (no) Terapeutiske forbindelser
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20063449L (no) Substituerte heterocykler og deres anvendelse
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
NO20092691L (no) 4-hydroksy-2-okso-2,3-dihydro-1,3-benzotiazol-7yl-forbindelser for modulering av B2-adrenoreseptoraktivitet
NO20073765L (no) Forbindelser for behandling av flaviviridae
TW200626585A (en) 18-membered macrocycles and analogs thereof
EA200601889A1 (ru) Лечение инфекционных заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application